OBSIDIAN
Live / Applied — First extension granted (statement of use) (as of 09 Jan 2026)
What this means for you
Not registered yet, but its 24 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99054448
- Mark type
- Stylized text
- Filed
- 24 Feb 2025
- Published for opposition
- 20 May 2025
- Attorney of record
- Olivia Maria Baratta
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations in the field of gene therapy for the prevention and treatment of cardio-vascular system disorders, genitourinary system disorders, immune system disorders, metabolic system disorders, musculo-skeletal system disorders, nervous system disorders, respiratory system disorders, inflammatory disorders, and gastroenterological disorders.
Owner
- Obsidian Therapeutics, Inc., Cambridge, MA, US
- Obsidian Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 10 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jan 2026 — SOU EXTENSION 1 GRANTED
- 09 Jan 2026 — SOU EXTENSION 1 FILED
- 09 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 May 2025 — PUBLISHED FOR OPPOSITION
- 14 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Apr 2025 — ASSIGNED TO EXAMINER
- 24 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Feb 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Feb 2025 — NEW APPLICATION ENTERED